|
市場調查報告書
產業分析：神經疾病市場的創新
Industry Analysis: Where Is the Innovation in Neurology Markets?
|
本報告已在2011年12月21日停止出版。
針對4大神經疾病現在沒有好的治療方法。大多數的藥品上市，也被成功開發出來，但是都是只針對一種症狀的藥。 治療神經疾病早期階段症狀的藥物還留有很大的發展空間。因此積極推動創新地藥品開發的企業將會有很多的機會。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. （總公司：麻薩諸塞州），針對神經疾病市場的創新趨勢進行調查分析，並系統整理調查結果後出版報告書 "Industry Analysis: Where Is the Innovation in Neurology Markets?" 。
本報告書內容包括：阿茲海默症、帕金森氏症、癲癇、多發性硬化症這4大神經疾病相關的藥物市場概要、企業的商業策略、追求神經疾病市場創新的重要決策、未來發展前景預測等。內容綱要摘記如下：
實施概要
沒有針對神經疾病的治療方法
全球的神經疾病市場
主要與神經疾病相關的授權
商業策略：2006年
- 10件主要的神經疾病交易：2005∼2006年
- 購併（M&A）
- 領導市場的多發性硬化症的權保益護
- 網羅非專利藥品到品牌藥品
- Sanofi-Aventis/Teva的Copaxone
- Teva/Lundbeck的Azilect
- 購併、透過內部授權的神經疾病治療藥產品線
- 完全整合企業
生命週期管理
- 帕金森氏症固定的併用藥物
- 疾病症狀加劇
- Rituxan/MabThera
- Zenapax
- Campath/MabCampath
- 重新配方
- Serono的Rebif
- Eisai 株式會社／Pfizer的Aricept
創新在哪裡
- 資源分配及優先選擇
- 引起疾病的基因及生物標記
- 為實現個人化醫療之藥物基因體學的利用
- 與幹細胞的關聯性如何
未來發展前景
參考資料
表
- 全球4大神經疾病：2004年、2005年
- 4大神經疾病的患者人數：2004年、2005年
- 全球的神經疾病相關授權：2005年
- 最大交易：2005年∼2006年
圖
- 前10大神經疾病相關品牌
- 神經疾病相關購併：2005年∼2006年
- Eisai株式會社的產品購併，透過授權制度強化神經疾病的授權系統
- 神經疾病藥品的生命週期管理
- 既有的單系統繁殖抗體及症狀
- 伴隨帕金森氏症的基因
- 第3階段之後發展階段的神經疾病藥品：2006年
Abstract
Introduction
The four major neurological diseases currently have no cures. Many
pharmaceuticals are available and are in development, but these drugs
typically address just the symptoms. Vast unmet need exists for medicines that
treat the early stages of neurological diseases. And, in turn, a huge
opportunity exists for companies that focus on innovation
Get the Answers You Need to Shape Your Strategy
There are more than a dozen major neurology franchises, and many companies
have had blockbuster success in this market. Yet the unmet need and resulting
opportunity in this market are staggering. What business strategies can
companies utilize to tap this wide-open market? Most medicines on the
market offer only symptomatic relief, and few new innovative drugs are in
development. What approaches can companies use to create drugs with
disease-modifying effects and to treat early-stage disease? Companies are
using many life-cycle management strategies to extend the market for existing
drugs. While these drugs are useful, they do little to build value for the
future. Why are so few products available for neurological diseases? What
explains the lack of innovation in this market? What strategies are companies
using to develop future neurology drug markets and franchises?
Scope
- Overview of drugs and market for the four major neurology diseases:
Alzheimer' s disease,Parkinson' s disease, epilepsy, and multiple sclerosis
- Key neurology deals: overview of ten neurology deals valued at more
than $100 million that have closed within the last two years
- Business strategies that companies are using to develop future
neurology drug markets and franchises: in-licensing, mergers and
acquisitions, fully integrated companies, challenging drug patents, extending
reach from generics to brands
- Decision points critical to innovation in the neurology market:
resource allocation and prioritization, how to treat early-stage disease,
creating personalized medicine, stem cell research
- Spectrum Expert Commentary: the view from a world-known
pharmaceutical industry consultant
- Outlook: challenges that the neurology market will face without
innovation
Mentioned in This Report-Companies
- Abbott Laboratories
- Acorda
- Albany Molecular Research
- Advanced
- Neurolomodulation
- Systems
- Alnylam
- Amarin
- Astellas
- AstraZeneca
- Athenagen
- Axaron Bioscience
- Axonyx
- Bayer AG
- BioArctic Neuroscience
- Bioceuticals Arzneimittel
- Biogen Idec
- BioMS
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Carlsson Research
- Celera Genomics
- CeNeS
- Chugai
- Cita NeuroPharmaceuticals
- CoCensys
- Dainippon
- DNAVEC
- Durect
- Eisai
- Elan
- Esteve
- Forest Labs
- Fumapharm
- GeneMedix
- Genzyme
- GlaxoSmithKline
- Ilex Oncology
- Image-Guided Neurologics
- Ivax
- Janssen
- Johnson & Johnson
- Kyowa Hakko Kogyo
- LION bioscience
- Lundbeck
- Medtronic
- Merck KGaA
- Millennium
- Pharmaceuticals
- MultiCell Technologies
- Mutual Pharmaceutical
- Mylan
- Myriad Genetics
- Neurochem
- Neurocrine
- NeuroSearch
- NeuroSolutions
- Newron Pharmaceuticals
- Nitto Denko
- Novartis
- Novasite
- NovImmune
- Orion
- Ortho-McNeil
- Osprey Pharmaceutical
- Ovation
- PDL BioPharma
- Pfi zer
- Prolong Pharma
- PsyCheNomics
- Purdue Pharma
- ReNeuron
- Rinat Neuroscience
- Roche
- Sanofi -Aventis
- Schering AG
- Schwarz Pharma
- Serono
- Shire
- Sigma-Tau
- Solvay
- St. Jude Medical
- Stem Cell Sciences
- Stem Cell Therapeutics
- StemCells
- Targacept
- Teva
- TorreyPines Therapeutics
- Transition Therapeutics
- TransTech Pharma
- UCB
- United Research
- Laboratories
- Valeant
- Vernalis
- Voyager
- Watson Laboratories
- XenoPort
- Zapaq
- Zenyaku Kogyo
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Neurological Diseases Have No Cures
- Worldwide Neurology Markets
- Major Neurology Franchises
- Business Strategies-2006
- Ten Largest Neurology Deals, 2005-2006
- Mergers & Acquisitions (M&As)
- Protecting a Market-Leading Multiple Sclerosis Franchise
- Risk Management of ��4-Integrin Inhibitors
- BG-12
- Extending Reach from Generics to Branded Pharmaceuticals
- Sanofi-Aventis/Teva' s Copaxone
- Teva/Lundbeck' s Azilect (rasagiline)
- Filling a Neurology Pipeline Through Acquisitions and Inlicensing
- Fully Integrated Companies
- Challenges from Generics and Biogenerics/Biosimilars Encroachment
- Sidebar: Demise of the Instant Fully Integrated Pharmaceutical Company
(FIPCO) Strategy
- Life-Cycle Management
- Fixed Combinations in Parkinson' s Disease
- Expanding Disease Indications
- Rituxan/MabThera
- Zenapax (daclizumab)
- Campath/MabCampath (alemtuzumab)
- Reformulations
- Serono' s Rebif
- Eisai/Pfizer' s Aricept
- Where Is the Innovation?
- Resource Allocation and Prioritization
- Disease-Causing Genes and Biomarkers
- Parkinson' s Disease
- Alzheimer' s Disease
- Epilepsy
- Using Pharmacogenomics to Create Personalized Medicines
- What' s Going on With Stem Cells?
- Outlook
Figures
- 1. Worldwide Markets for Four Major Neurology Diseases, 2004/2005
- 2. Prevalence of Four Major Neurology Diseases, 2004/2005
- 3. Major Worldwide Neurology Franchises, 2005
- 4. Largest Neurology Deals, 2005-2006
Tables
- 1. Top Ten Neurology Brands
- 2. Select Neurology-Based Mergers and Acquisitions, 2005-2006
- 3. Strengthening Eisai' s Neurology Franchise Through Product Acquisitions
and Licensing
- 4. Life-Cycle Management of Select Neurology Drugs
- 5. Extending Disease Indications for Existing Monoclonal Antibodies
- 6. Genes Associated with Parkinson' s Disease
- 7. Neurology Drugs in Phase III Development or Later, 2006
|
